Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RARA | P10276 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19864297 | 0.88 | ALDH1A1 (0.55) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL9456708 | 0.86 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL8823134 | 0.86 | GABRA2 (0.50) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL31526177 | 0.84 | GABRA2 (0.56) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL14953420 | 0.84 | CYP1A2 (0.57) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL6255264 | 0.82 | PTGER1 (0.51) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL6255283 | 0.79 | PTGER1 (0.46) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL6274152 | 0.78 | GABRA2 (0.59) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL7989910 | 0.78 | RAB9A (0.49) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL20027814 | 0.77 | SMN1; SMN2 (0.55) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098545-A1 | NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2025-05-15 | — | — | WO | disclosed |
| EP-4553080-A1 | NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2025-05-14 | — | — | EP | disclosed |
| WO-2005066137-A1 | 2,5-DIARYL-1H-IMIDAZOLE-4-CARBOXAMIDES AS NEUROKININ-3 RECEPTOR MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES | NEUROGEN CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050148601-A1 | Neurokinin-3 receptor modulators: diaryl imidazole derivatives | NEUROGEN CORPORATION | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148601-A1 | Neurokinin-3 receptor modulators: diaryl imidazole derivatives | TACR1, TACR2, TACR3 | CYP1A2 1918/4885CYP2C9 2473/4885CYP2C19 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.